Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Litx
- Development stage
- Discontinued
- Lead developer
- Eddingpharm
- Modality
- Small Molecules
- Administration
- Intravenous, Intratumoral
01
Overview
Litx is a photodynamic therapy (PDT) system developed by Light Sciences Oncology for the treatment of solid tumors, including unresectable hepatocellular carcinoma (HCC). The system consists of talaporfin sodium, a second-generation photosensitizer, and a proprietary light-emitting diode (LED) catheter. Talaporfin sodium is administered intravenously and selectively accumulates in tumor cells and vascular endothelium. The LED catheter is then positioned within the tumor to deliver a specific wavelength of light (664 nm), which excites the photosensitizer. This excitation leads to the production of singlet oxygen and other reactive oxygen species, causing localized oxidative stress that results in tumor cell apoptosis, necrosis, and the collapse of tumor microvasculature. Despite reaching Phase 3 trials for HCC (the FOCUS study) and cholangiocarcinoma, the development of Litx was terminated after the FOCUS trial failed to demonstrate a significant improvement in overall survival compared to standard care.
- Brand names
- LitxAptocine
- Other names
- talaporfin sodiummono-L-aspartyl chlorin e6NPe6NPe-6NPe 6taltorfin sodiumLaserphyrin
Beyond the preview
Go deeper on Litx.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Litx.